GSK receives FDA approval for dissolvable Lamictal

05/11/2009 | Forbes

GlaxoSmithKline obtained FDA clearance to launch a soluble formulation of Lamictal, a treatment for epilepsy and bipolar disorder. Lamictal ODT is expected to be on the market by July in doses of 25, 50, 100 and 200 milligrams, GSK said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
Boise, ID